Cargando…

Liver fibrosis in patients with chronic liver diseases: are laboratory tests useful to diagnosis?

Detalles Bibliográficos
Autores principales:	Leonardi, Salvatore, Vitaliti, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2011
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212774/ https://www.ncbi.nlm.nih.gov/pubmed/22087168

Ejemplares similares

Indirect markers of fibrosis in chronic liver diseases: Is aspartate transaminase-to-platelet ratio (APRI) a useful test?
por: Corte, Claudia Della, et al.
Publicado: (2011)

Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease?
por: Parsian, Hadi
Publicado: (2011)

Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease
por: Anania, Caterina, et al.
Publicado: (2011)

Commentary on: Noninvasive assessment of liver fibrosis using aspartate transaminase to platelet ratio index (APRI) in adult patients with chronic liver disease
por: El-Shabrawi, Mortada, et al.
Publicado: (2011)

The Hepatitis B Vaccine and Celiac Disease: More Lights Than Shadows?
por: Vitaliti, Giovanna, et al.
Publicado: (2013)

Two or More Synchronous Combination of Noninvasive Test to Increase Accuracy of Liver Fibrosis in Chronic Hepatitis C
por: Testa, Roberto
Publicado: (2012)

Noninvasive Methods to Evaluate Liver Fibrosis in Chronic HCV Infection
por: El-Shabrawi, Mortada Hassan, et al.
Publicado: (2011)

Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases
por: Mao, Yilei, et al.
Publicado: (2011)

Liver Disease in Cystic Fibrosis: an Update
por: Parisi, Giuseppe Fabio, et al.
Publicado: (2013)

Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis
por: Sirli, Roxana, et al.
Publicado: (2011)

Would the Physicians Eventually Obsolete the Liver Biopsy for the Assessment of Liver Fibrosis?
por: Parsian, Hadi, et al.
Publicado: (2012)

Therapeutic potentials of fasudil in liver fibrosis
por: Xi, Yue, et al.
Publicado: (2021)

Correspondence to Levetiracetam in Neonatal Seizures as First-Line Treatment
por: Falsaperla, Raffaele, et al.
Publicado: (2018)

RE: Liver Shear-Wave Velocity to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B
por: Ozturker, Coskun, et al.
Publicado: (2016)

Liver fibrosis causes periportalization of lobular zonation
por: Seddek, Abdellatief
Publicado: (2019)

Celiac Disease and Abnormal Liver Function Test
por: Nejad, Mohammad Rostami, et al.
Publicado: (2012)

Association of chronic liver disease with the prognosis of COVID-19 patients
por: Long, Junyu, et al.
Publicado: (2022)

The Concept of Liver Disease Diagnosis in Avicenna’s Canon of Medicine
por: SHAHKARAMI, Efat, et al.
Publicado: (2013)

Nosocomial candiduria in chronic liver disease patients at a hepatobilliary center
por: Ahmed, Armin, et al.
Publicado: (2014)

Reply to: “Association of chronic liver disease with the prognosis of COVID-19 patients”
por: Mallet, Vincent, et al.
Publicado: (2022)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Can We Accurately Assess Liver Fibrosis with Fibroscan® Using Fewer Valid Measurements?
por: Pournik, Omid, et al.
Publicado: (2013)

Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease
por: Hong, Jian-Guo, et al.
Publicado: (2022)

The imbalance of procoagulant and anticoagulant factors in patients with chronic liver diseases in North India
por: Saxena, Priyanka, et al.
Publicado: (2017)

Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score
por: Guan, Yong-Song
Publicado: (2014)

Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?
por: Izzy, Manhal, et al.
Publicado: (2021)

Strategies for a two-step liver fibrosis assessment in clinical practice
por: Vieira Barbosa, Joana, et al.
Publicado: (2021)

Does CB-1 in hepatic stellate cells contribute to liver fibrosis?
por: Lotersztajn, Sophie, et al.
Publicado: (2022)

What is the performance of the Aspartate Aminotransferase to platelets Ratio Index in patients With Chronic Liver Disease?
por: Zarski, Jean Pierre
Publicado: (2011)

Clinical characteristics of COVID-19 patients with abnormal liver tests
por: Chen, Peng, et al.
Publicado: (2020)

Liver transplantation for very severe hepatopulmonary syndrome due to vitamin A-induced chronic liver disease in a patient with Shwachman-Diamond syndrome
por: Bucciol, Giorgia, et al.
Publicado: (2018)

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
por: Cheung, Ka Shing, et al.
Publicado: (2023)

Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients
por: Soto, Marcelo, et al.
Publicado: (2017)

Should people with chronic liver diseases be vaccinated against COVID-19?
por: Chen, Li-Ping, et al.
Publicado: (2021)

Acute-on-Chronic Liver Failure Remains a Minor Indication for Liver Transplant in Portugal
por: Cardoso, Filipe S., et al.
Publicado: (2023)

Effect of Ramadan Fast on Liver Function Tests
por: Nasiri, Jafar, et al.
Publicado: (2016)

Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI)
por: Adler, Michael
Publicado: (2011)

Reply to: “Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?”
por: Allaire, Manon, et al.
Publicado: (2021)

Poor Response to Inactivated SARS-CoV-2 Vaccine in Patients With Chronic Liver Disease
por: Cao, Huanhuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b9ogtq1g28r6odnsk34g7s4j2j